Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01751802 · ClinicalTrials.gov registry record · Phase 3
Ecopipam Treatment of Self-Injurious Behavior in Subjects With Lesch-Nyhan Disease
A Phase 3 study, sponsored by Emalex Biosciences.
- Terminated
- Registry status
- Phase 3
- Development phase
- 9
- Enrollment target
NCT01751802 is a Phase 3 study that was terminated before completion, run by Emalex Biosciences. The registered enrollment target is 9 participants.
The verdict
NCT01751802, a Phase 3 study, was terminated before completion, sponsored by Emalex Biosciences.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 9 participants
- Enrollment target
Study Summary
The purpose of this research study is to gather scientific information about the effectiveness and safety of the study drug, Ecopipam (PSYRX 101), for the treatment of self-injurious behaviors when compared with the effectiveness and safety of placebo (inactive substance) in subjects with Lesch-Nyhan Disease.
Interventions
- DRUG Placebo
- DRUG Ecopipam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2012-12 |
| Est. Completion | 2014-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01751802
The ClinicalTrials.gov registry entry for NCT01751802 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emalex Biosciences, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01751802 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01751802 about?
NCT01751802 is a clinical study titled "Ecopipam Treatment of Self-Injurious Behavior in Subjects With Lesch-Nyhan Disease". The purpose of this research study is to gather scientific information about the effectiveness and safety of the study drug, Ecopipam (PSYRX 101), for the treatment of self-injurious behaviors when compared with the effectiveness and safety of placebo (inactive substance) in subjects with Lesch-Nyha...
What is the current status of trial NCT01751802?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 9 participants. The study started on 2012-12. Estimated completion is 2014-12.
What interventions are being tested in trial NCT01751802?
The interventions under investigation include: Placebo (DRUG), Ecopipam (DRUG).
Who is sponsoring clinical trial NCT01751802?
This trial is sponsored by Emalex Biosciences, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.